Press releases
2020. 07. 26
- NH Investment
& Securities wereed as the lead underwriter and Korea Investment
& Securities as the co-underwriter for SK bioscience’s IPO.
- SK bioscience plans to be listed for the next year to expand business and
accelerate growth by securing new investment
SK bioscience announced that the company hased the
NH Investment & Securities as a lead underwriter and Korea Investment &
Securities as its co-underwriter to manage an initial public offering (IPO) for
2021.
SK bioscience plans to expand its business and
accelerate further growth by securing new investment.
SK bioscience has developed SKYCellflu®
Quadrivalent, the world´s first cell culture-based quadrivalent influenza
vaccine, SKYZoster®, the world´s second shingles
vaccine, and SKYVaricella®, the second varicella vaccine developed in Korea.
New products currently being developed include a COVID-19 vaccine and a next-generation
pneumococcal vaccine.
SK bioscience has been actively advancing to overseas
markets and expanding its business portfolio. The company recently signed a CMO
contract with AstraZeneca, a global pharmaceutical company, to supply COVID 19
vaccines in Korea and abroad.
A company official said, "The IPO will be conducted
under proper evaluation.”